NCT04643587View on ClinicalTrials.gov

Study to Assess CSL787 in Non-cystic Fibrosis Bronchiectasis (NCFB)

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

December 7, 2020

Primary Completion Date

March 12, 2023

Study Completion Date

March 12, 2023

Conditions
Noncystic Fibrosis Bronchiectasis (NCFB)
Interventions
BIOLOGICAL

CSL787

Human plasma-derived polyvalent immunoglobulin G (IgG) administered via inhalation of an aerosol produced using a nebulizer

DRUG

Placebo

Normal saline (0.9% NaCl)

Trial Locations (3)

Unknown

IKF Pneumologie Institute, Frankfurt

M23 9QZ

Medicines Evaluation Unit (MEU), Manchester

BT9 6AD

Celerion, Belfast

Sponsors

Lead Sponsor

CSL Behring
All Listed Sponsors
lead

CSL Behring

INDUSTRY

NCT04643587 - Study to Assess CSL787 in Non-cystic Fibrosis Bronchiectasis (NCFB) | Biotech Hunter | Biotech Hunter